Quick Summary
- Dasatinib + Quercetin (D+Q) is the most validated senolytic combination in human research, with completed clinical trials in idiopathic pulmonary fibrosis and diabetic kidney disease.
- Dasatinib hits senescent cells dependent on src-family kinase survival signaling. Quercetin hits senescent cells dependent on BCL-xL anti-apoptotic protein. Different cell types, complementary mechanisms.
- Standard protocol: dasatinib 100mg + quercetin 1000mg, two consecutive days, once monthly or quarterly.
- Pulse dosing — not chronic. Senolytic clearance is an event, not a daily intervention.
- The Natural Plus angle: stack D+Q with fisetin for broader senescent cell coverage, and pair with BPC-157 in the week following clearance.
Senolytics is one of the highest-leverage interventions in modern longevity science. The basic premise — that selectively killing senescent cells reverses functional aging — has held up across multiple labs, multiple species, and now in early human clinical trials. The question Enhanced Men actually need answered is not whether senolytics work. The question is which protocol works, at what dose, on what schedule.
Dasatinib + Quercetin (D+Q) is the answer with the most human data behind it. Here is how the protocol actually runs.
The Biochemistry: Why The Combination Beats Either Alone
Senescent cells are not a single type of cell. They are a category. Senescent fibroblasts, senescent endothelial cells, senescent adipocytes, and senescent immune cells use different anti-apoptotic survival mechanisms. A senolytic that hits one survival pathway will clear one population and miss the others.
Dasatinib is a tyrosine kinase inhibitor — originally a leukemia drug — that disrupts src-family kinase signaling. Senescent cells that depend on this pathway for survival (predominantly senescent preadipocytes and certain endothelial cells) die when dasatinib hits.
Quercetin is a flavonoid that disrupts BCL-xL, the anti-apoptotic protein. Senescent endothelial cells and senescent mesenchymal stem cells use BCL-xL upregulation to evade apoptosis. Quercetin breaks that defense.
Together, the combination clears a broader fraction of total senescent cell burden than either compound alone. The synergy is not pharmacokinetic — it is mechanistic. Two independent receptor systems, two independent vulnerabilities, hit simultaneously. That is Law 5 of the Tony Huge Laws of Biochemistry Physics in action: Independent Receptor Stacking.
The Human Trial Data
The Mayo Clinic ran the first open-label human trial of D+Q in idiopathic pulmonary fibrosis in 2018-2019. Patients received dasatinib 100mg + quercetin 1250mg for 3 consecutive days per week for 3 weeks. The result: measurable improvement in 6-minute walk distance, 4-meter gait speed, and chair-rise time. Translation: senolytic therapy improved physical function in patients with a degenerative lung disease.
The same group then ran D+Q in diabetic kidney disease. The published 2019 data showed reduced senescent cell markers in adipose tissue biopsies and skin biopsies — direct evidence that the protocol clears senescent cells in humans, not just mice.
Multiple follow-up trials are ongoing in Alzheimer’s disease, post-COVID frailty, and chronic kidney disease. The current Mayo Clinic protocol for general research use clusters around 100mg dasatinib + 1000mg quercetin for 2 consecutive days, repeated monthly or quarterly.
Natural Plus Protocol
The underground D+Q protocol that has emerged from the bodybuilding-longevity intersection looks slightly different from the formal trial doses. It is more conservative and runs less frequently.
- Dose: Dasatinib 100mg + Quercetin 1000mg.
- Schedule: Two consecutive days. Day 1 and Day 2 in the morning with food.
- Frequency: Once monthly for the first 3 months, then quarterly thereafter.
- Timing: Take in the morning to allow daytime clearance of apoptotic debris.
- Pre-protocol bloodwork: CRP, ESR, comprehensive metabolic panel, CBC, lipid panel. Get an EKG if you are over 50 — dasatinib has dose-dependent QT effects.
- Post-protocol support: BPC-157 250-500 mcg daily for 7-14 days after dosing supports tissue repair in cleared niches.
- Hydration: 3-4 liters water on dosing days. The apoptotic debris is renally cleared.
- Avoid: Grapefruit, strong CYP3A4 inhibitors, and most other medications for 48 hours pre/post dosing. Dasatinib has significant drug interactions.
Stacking Recommendations
D+Q stacks well with senolytics hitting different mechanisms (alternating cycles, not simultaneous) and with regenerative compounds during the post-clearance window:
- Fisetin — broad-spectrum senolytic with a different mechanism. Run fisetin between D+Q cycles to cover senescent cell types both miss. See fisetin protocol.
- FOXO4-DRI — alternative senolytic with mechanistic selectivity. Some users alternate D+Q and FOXO4-DRI cycles. See FOXO4-DRI deep dive.
- BPC-157 — tissue repair in the cleared niches. See BPC-157.
- Spermidine — autophagy activator that supports cellular cleanup adjacent to apoptotic clearance. See spermidine.
Target Audience
D+Q makes sense for: Enhanced Men over 40 with elevated inflammatory markers (CRP, ESR), people with chronic injuries that have stopped healing, anyone with metabolic syndrome features. Not for: people on antiplatelets or anticoagulants, anyone with QT prolongation or cardiac arrhythmia history, anyone on medications with major CYP3A4 interactions.
Timeline / Results
| Timeframe | What to Expect |
|---|---|
| Dosing days | Mild fatigue, sometimes flu-like symptoms (the SASP cleanup signal). |
| Week 1-2 post-dose | Inflammation markers drop, joint stiffness eases. |
| Week 4 | Sustained CRP reduction, training recovery noticeably better. |
| Month 3 | Decision point: continue monthly or shift to quarterly maintenance. |
Interesting Perspectives
The conversation the senolytics community is having in 2026 that nobody outside the field knows about: monthly D+Q may be too aggressive for some users. The Mayo trials used short courses with months between. Some researchers now argue that quarterly is the right frequency for long-term use, and monthly is appropriate only for catch-up clearance in users with high baseline senescent burden. Track your inflammatory markers and use them as the signal for when to dose again.
Contrarian take: the most overlooked element of the D+Q protocol is the post-dosing support. Killing senescent cells is the easy part. Supporting the tissue regeneration that should fill the cleared niches is what determines whether you actually feel better. BPC-157 in the week after dosing is doing more functional work than the senolytic itself. Most protocols ignore this.
Cross-domain connection: dasatinib was originally a leukemia drug. Its senolytic application is an off-target effect that became therapeutic. This pattern — drug developed for one indication, repurposed off-label for longevity — is going to become more common as the longevity field matures. Rapamycin, metformin, and now dasatinib are all examples. The hypocrisy angle: when bodybuilders use compounds off-label they are called drug abusers. When longevity researchers use compounds off-label they are called pioneers. Same activity, different framing.
FAQ
What is the standard dasatinib + quercetin dose? 100mg dasatinib + 1000mg quercetin, taken on two consecutive days, repeated monthly or quarterly.
How often should I run D+Q? Monthly for the first three months if you have high inflammatory burden, then transition to quarterly maintenance.
Do I need a prescription for dasatinib? Dasatinib is a prescription drug in most jurisdictions. Off-label senolytic use is at the prescriber’s discretion or through research-chemical channels.
What bloodwork should I track? CRP, ESR, comprehensive metabolic panel, CBC, lipid panel before each cycle. Look for downward trends in CRP and ESR as the marker that the protocol is working.
Can I stack D+Q with fisetin or FOXO4-DRI? Yes, but alternate cycles rather than run them simultaneously. The combinations cover different senescent cell populations.
Cross-Reference
For the foundational longevity stack see the Enhanced Athlete Protocol hub. For the senolytics overview see senolytics and zombie cells. For tissue repair in the post-clearance window see Protocol: Peptides. For bloodwork tracking see Protocol: Bloodwork.